Pharma firms choosing to run more phase-IV trials
The number of voluntarily initiated phase-IV clinical trials has increased in recent years, a study has found.
There has been an increase in the number of phase-IV clinical trials being initiated voluntarily by pharmaceutical companies, new research shows.
Phase-IV trials are sometimes required by regulators after a new drug or medical device has been launched.
But an increasing number of pharmaceutical companies are recognising the benefits of phase-IV trial data and are initiating them of their own accord, according to research firm Cutting Edge Information.
The company's study found that 82 per cent of drug manufacturers' post-marketing trials are now started voluntarily, compared with just 61 per cent in 2006.
Meanwhile, the percentage of post-marketing trials that were required by regulatory bodies fell from 39 per cent in 2006 to 17 per cent in 2011.
David Richardson, research manager at Cutting Edge Information, said that the increase in voluntarily initiated phase-IV trials "points to a trend where pharma companies have taken greater control of their futures".
He added: "The bottom line is safety. Health outcomes and pharmacoeconomic data is more important than ever before."
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance